• Product name

    Anti-Factor H antibody [OX23]
    See all Factor H primary antibodies
  • Description

    Mouse monoclonal [OX23] to Factor H
  • Host species

  • Tested applications

    Suitable for: ELISAmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Full length native protein (purified from plasma) (Human).



Our Abpromise guarantee covers the use of ab17928 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/250000.


  • Function

    Factor H functions as a cofactor in the inactivation of C3b by factor I and also increases the rate of dissociation of the C3bBb complex (C3 convertase) and the (C3b)NBB complex (C5 convertase) in the alternative complement pathway.
  • Tissue specificity

    Expressed by the liver and secreted in plasma.
  • Involvement in disease

    Genetic variations in CFH are associated with basal laminar drusen (BLD) [MIM:126700]; also known as drusen of Bruch membrane or cuticular drusen or grouped early adult-onset drusen. Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch membrane. Basal laminar drusen refers to an early adult-onset drusen phenotype that shows a pattern of uniform small, slightly raised yellow subretinal nodules randomly scattered in the macula. In later stages, these drusen often become more numerous, with clustered groups of drusen scattered throughout the retina. In time these small basal laminar drusen may expand and ultimately lead to a serous pigment epithelial detachment of the macula that may result in vision loss.
    Defects in CFH are the cause of complement factor H deficiency (CFH deficiency) [MIM:609814]. CFH deficiency determines uncontrolled activation of the alternative complement pathway with consumption of C3 and often other terminal complement components. It is associated with a number of renal diseases with variable clinical presentation and progression, including membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. CFH deficiency patients may show increased susceptibility to meningococcal infections.
    Defects in CFH are a cause of susceptibility to hemolytic uremic syndrome atypical type 1 (AHUS1) [MIM:235400]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
    Genetic variation in CFH is associated with age-related macular degeneration type 4 (ARMD4) [MIM:610698]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid (known as drusen) that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
  • Sequence similarities

    Contains 20 Sushi (CCP/SCR) domains.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • adrenomedullin binding protein antibody
    • age related maculopathy susceptibility 1 antibody
    • AHUS 1 antibody
    • AHUS1 antibody
    • AMBP 1 antibody
    • AMBP1 antibody
    • ARMD 4 antibody
    • ARMD4 antibody
    • ARMS 1 antibody
    • ARMS1 antibody
    • beta 1 H globulin antibody
    • beta 1H antibody
    • beta1H antibody
    • CFAH_HUMAN antibody
    • CFH antibody
    • CFHL 3 antibody
    • CFHL3 antibody
    • Complement factor H antibody
    • complement factor H, isoform b antibody
    • Factor H antibody
    • factor H like 1 antibody
    • FH antibody
    • FHL 1 antibody
    • FHL1 antibody
    • H factor 1 (complement) antibody
    • H factor 1 antibody
    • H factor 2 (complement) antibody
    • HF 1 antibody
    • HF 2 antibody
    • HF antibody
    • HF1 antibody
    • HF2 antibody
    • HUS antibody
    • MGC88246 antibody
    see all


This product has been referenced in:

  • Swinkels M  et al. C-reactive protein and pentraxin-3 binding of factor H-like protein 1 differs from complement factor H: implications for retinal inflammation. Sci Rep 8:1643 (2018). Read more (PubMed: 29374201) »
  • Clark SJ  et al. Bruch's Membrane Compartmentalizes Complement Regulation in the Eye with Implications for Therapeutic Design in Age-Related Macular Degeneration. Front Immunol 8:1778 (2017). Read more (PubMed: 29312308) »
See all 3 Publications for this product

Customer reviews and Q&As

1-4 of 4 Abreviews or Q&A


Thank you for your enquiry and I'm sorry to hear that you are experiencing difficulty with this antibody. At this point I would like to make the following suggestions in order to try to improve your results. Try blocking the membrane with 3% BSA. You mentioned loading 180 ug of protein onto your gel which is quite a high amount; I would suggest loading between 20-30 ug of lysate. Decrease the concentration of your primary(ab17928); try 1:1000 and 1:2000 and incubate at RT for 2 hrs. The secondary is probably fine, but you also want to check this by running a secondary-only control (omit the primary and incubate with the secondary antibody only) to ensure that the background is not due to the secondary antibody. Increase the number of washes that you are doing. Finally, I don't know if you are using a nitrocellulose or PVDF membrane, but a nitrocellulose membranes is considered to give less background than a PVDF membrane. Please let me know if these suggestions are helpful, and have a nice weekend.

Read More


ab17928 was originally tested in Western blot for specificity to Factor H, but we do not know the optimum dilution. The optimum dilution must be determined by the individual in his or her experiments. We do not have data on human eye tissue, but see no reason why it should not work. The antibody was raised against the 155 kDa Factor H. We do not have data on reactivity with other forms. Please do not hesitate to contact us again if you need further assistance,

Read More


Thank you for your enquiry. To our knowledge this antibody only recognizes full length compliment factor H. We have yet to test this antibody against truncated region of compliment factor H. Best of luck with your research.

Read More


Thank you for your enquiry regarding ab17928. Unfortunately, the epitope has not been mapped and the antibody has not been tested for cross-reactivity with complement factor H-like proteins. Furthermore, I was unable to find out further information regarding the WB protocol, I am very sorry for the inconvenience. I am sorry for the lack of information about this clone.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up